NANJING, China, November 23, 2023 /PRNewswire/ — The 6thth The China International Import Expo (CIIE) was held in Shanghai, China on November 5, 2023. Nanjing IASO Biotechnology Co.,Ltd. (IASO Bio) debuted at CIIE with FUCASO, the world’s first fully human CAR-T, and entered into a strategic partnership with several international medical institutions, bringing hope of a cure to multiple myeloma patients (MM) worldwide. As a biopharmaceutical company engaged in the R&D, production and sales of innovative cellular drugs, IASO Bio not only develops CAR-T therapies meeting international standards for Chinese patients, but also actively promotes international clinical trials, thereby demonstrating its scientific research and innovation capabilities. .
World’s first fully human CAR-T makes significant debut
On June 30, 2023, the China National Medical Products Administration (NMPA) has approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCASO) for the treatment of adult patients with relapsed or refractory multiple myeloma (r/rMM). In the meantime, THE Equecabtagene Autoleucel Injection received orphan drug designation, as well as advanced regenerative medicine therapy and fast-track designations from the United States Food and Drug Administration, and was approved for clinical trials in United States.
A single infusion of FUCASO can lead to durable and deep remission with a favorable safety profile in patients with R/R MM who have failed multiple lines of therapy. With its unique design, FUCASO, as a fully human CAR-T therapy, is able to persist in patients for a longer period, providing hope for overcoming the difficult problem of relapsed MM.
Establishment an international center for CAR-T diagnosis and treatment
FUCASO has attracted patients from many countries around the world, including Asia, EuropeOceania and Africaforthcoming China for treatment in just 4 months since its marketing approval in China. Many patients in the first batch had primary drug resistance, multiple drug resistance and high cytogenetic risk, and after treatment with FUCASO, they achieved complete remission and minimal residual disease negativity.
At present, several authoritative hospitals for the treatment of hematologic malignancies in China have established FUCASO certified treatment centers and are recognized globally for their cutting-edge level of comprehensive management of the CAR-T treatment process. It should be noted that the cost of treatment with FUCASO in China is significantly lower than that of similar products in Europe and America, which improved the accessibility of this innovative medicine and benefited MM patients worldwide.
In addition, IASO Bio has established strategic partnerships with a number of international medical institutions to jointly build an international CAR-T diagnosis and treatment center to serve patients around the world.
Show original content:https://www.prnewswire.com/apac/news-releases/iaso-bio-establishes-international-car-t-diagnostic-and-treatment-center-in-china-to-serve-mm-patients-worldwide- 301996532.html
SOURCE Nanjing IASO Biotechnology Co., Ltd
